Goodsurance

Drug prices & Part D

Lower prices on 15 drugs arrive in 2027

Medicare's negotiated prices for 15 widely used medicines take effect this coming January. Here is what that changes, and what it does not, for your own pharmacy bill.

By the Goodsurance editorial teamJuly 1, 2026

Starting January 1, 2027, Medicare's first round of negotiated prices on a second set of 15 high cost drugs takes effect. Public reporting has identified the popular diabetes and weight loss medicines Ozempic and Wegovy among them, alongside treatments for other common conditions. Medicare says that if these negotiated prices had been in place in 2024, they would have lowered net Medicare drug spending by about 8.5 billion dollars, or roughly 36 percent on those drugs. This builds on the first ten negotiated prices that took effect in January 2026, and Medicare is still refining the program, with a proposed update published June 12, 2026 and open for public comment through August 17. Here is the honest read for your own wallet. A negotiated price lowers what the Medicare program pays for a drug, which helps hold down overall costs and can ripple into plan pricing. What you personally pay at the pharmacy still depends on your specific plan, its formulary, and where you are in the year. For most people, the bigger everyday protection is the annual cap on out of pocket drug costs, reported at 2,100 dollars for 2026, which limits your total spending on covered drugs no matter how expensive they are. So the takeaway is not to switch anything today. It is to know that lower negotiated prices are coming for these drugs in January, and to compare plans this fall on how they actually cover the medicines you take. The pointed debate over whether negotiation goes far enough or discourages new drug research routes to my65checklist; here the job is to explain what changes in January and what your copay still hinges on.

In plain words

Medicare can now negotiate the price of some very costly drugs. The first ten lower prices started in January 2026. Now a second group of 15 drugs gets lower prices, starting January 1, 2027. News reports say two of them are the well known drugs Ozempic and Wegovy. Medicare says these prices could cut its drug spending by about 8.5 billion dollars, roughly 36 percent on those drugs. Here is what it means for you. A negotiated price lowers what Medicare pays. What you pay at the pharmacy still depends on your own plan and the time of year. For most people, the bigger help is the yearly limit on what you pay out of pocket for covered drugs, set at 2,100 dollars for 2026. That caps your total no matter how pricey the drug. You do not need to do anything today. Just know the lower prices are coming in January, and when you shop this fall, check how each plan covers the drugs you take.

Source: Centers for Medicare and Medicaid Services
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

KFF: Medicare Advantage Drug Plans Received Over 600 Dollars Per Member in Rebates That Standalone Drug Plans Cannot Access

A KFF analysis explains the structural payment asymmetry that makes it harder for standalone Part D plans to compete on drug premiums, as the number of those plans hits record lows ahead of open enrollment.

August 8, 2026

Drug prices & Part D

Bipartisan Senate Bill Would Preserve Drug Discounts for Safety-Net Hospitals and Shut Down a Rebate Pilot

Six senators from both parties introduced the SUSTAIN 340B Act on August 5, proposing to protect point-of-purchase drug discounts for safety-net providers while adding new transparency and audit requirements.

August 6, 2026

Drug prices & Part D

CMS Counted a 2020 Reclassification Date for Creon, Delaying Medicare Price Talks by Years, Report Says

Public Citizen says CMS allowed AbbVie to use the date Creon was reclassified as a biologic rather than its original FDA approval date, pushing the drug's eligibility for Medicare price negotiation years into the future.

August 5, 2026

Drug prices & Part D

Medicare Part D Deductible Rises to 700 Dollars and Out-of-Pocket Drug Cap Reaches 2,400 Dollars for 2027

The Inflation Reduction Act tied the Medicare Part D annual deductible and catastrophic spending limit to drug cost growth, and both parameters rise again for 2027, continuing an upward pattern as specialty and GLP-1 drug spending climbs across the program.

August 4, 2026

Drug prices & Part D

Medicare and Drug Manufacturers Are Holding Negotiation Meetings This Summer on 15 High-Cost Drugs, With Final Prices Due by November

The third cycle of Medicare drug price negotiations is in its most active phase, with CMS and participating manufacturers in sessions that must conclude by November 1, 2026, to set maximum fair prices on cancer, HIV, and other specialty drugs taking effect in 2028.

August 3, 2026

Drug prices & Part D

CMS Confirms the 2027 Medicare Part D Base Premium at 41 Dollars and 33 Cents as a Federal Stabilization Subsidy for Drug Plans Ends

The confirmed base premium equals the maximum 6 percent annual increase the Inflation Reduction Act allows, but consumer advocates warn that actual plan-level premiums, which are set above that floor, are likely to climb sharply once a temporary federal subsidy expires at year-end.

July 30, 2026